Latest News for: fsgs

Edit

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI� (sparsentan) for the Treatment of FSGS

Nasdaq Globe Newswire 17 Mar 2025
Travere announces sNDA submission to FDA based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS, a rare kidney condition ... .
  • 1
×